RNA (Atrium Therapeutics) EBITDA Margin %: -87.24% (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics EBITDA Margin %?

Atrium Therapeutics RNA +0.16% 12 EBITDA Margin % is -87.24% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Atrium Therapeutics ranks worse than 67.2% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Atrium Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-17.13 Mil. Atrium Therapeutics's Revenue for the three months ended in Mar. 2026 was $19.64 Mil. Therefore, Atrium Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -87.24%.

Atrium Therapeutics  (NAS:RNA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Atrium Therapeutics EBITDA Margin % Related Terms

Atrium Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics EBITDA Margin % Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
EBITDA Margin %
-63.99 -119.72 -410.84

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial -208.31 -470.38 0.00 -5,577.76 -87.24

RNA vs RNAC, KROS, ARCT: EBITDA Margin % Comparison

For the Biotechnology subindustry, Atrium Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's EBITDA Margin % falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Atrium Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-76.491/18.618
=-410.84 %

Atrium Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.129/19.635
=-87.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -87.24% mean?
Atrium Therapeutics (RNA) has a EBITDA Margin % of -87.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Atrium Therapeutics and its competitors. According to the industry distribution chart, Atrium Therapeutics ranks #635 out of 945 companies in the Biotechnology industry, placing it in the top 67.2%.
Is Atrium Therapeutics' EBITDA Margin % too high?
Atrium Therapeutics' current EBITDA Margin % is -87.24%. Based on the distribution chart, Atrium Therapeutics ranks #635 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' EBITDA Margin % compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #635 out of 945 companies for EBITDA Margin %. This places Atrium Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current EBITDA Margin % is -87.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current EBITDA Margin % of -87.24%. The current EBITDA Margin % is -87.24%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current EBITDA Margin % is -87.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price